Voyager Therapeutics Enters Material Definitive Agreement
Ticker: VYGR · Form: 8-K · Filed: Sep 5, 2024 · CIK: 1640266
Sentiment: neutral
Topics: material-definitive-agreement, contract
TL;DR
Voyager Therapeutics signed a big deal on Sept 3rd, details TBD.
AI Summary
On September 3, 2024, Voyager Therapeutics, Inc. entered into a material definitive agreement. The filing does not disclose the specific nature of the agreement or any associated dollar amounts.
Why It Matters
This filing indicates a significant new contract or partnership for Voyager Therapeutics, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — The lack of specific details in the filing regarding the material definitive agreement introduces uncertainty about its terms and potential impact.
Key Players & Entities
- Voyager Therapeutics, Inc. (company) — Registrant
- September 3, 2024 (date) — Date of Earliest Event Reported
FAQ
What is the nature of the material definitive agreement entered into by Voyager Therapeutics?
The filing states that Voyager Therapeutics, Inc. entered into a material definitive agreement on September 3, 2024, but does not provide specific details about the agreement's terms or purpose.
Are there any financial terms disclosed in relation to this agreement?
No, the provided text of the 8-K filing does not disclose any specific dollar amounts or financial terms associated with the material definitive agreement.
Who are the parties involved in this material definitive agreement?
The filing identifies Voyager Therapeutics, Inc. as the registrant entering into the agreement, but does not name the other party or parties involved.
What is the significance of filing an 8-K for a material definitive agreement?
An 8-K filing is required to report material events that are of importance to shareholders, such as entering into a significant contract or agreement.
When was this agreement officially reported?
The 8-K filing was made on September 5, 2024, and the earliest event reported is September 3, 2024, which is the date of the agreement.
Filing Stats: 732 words · 3 min read · ~2 pages · Grade level 13.1 · Accepted 2024-09-05 08:06:12
Key Financial Figures
- $0.001 — ge on which registered Common Stock, $0.001 par value VYGR Nasdaq Global Select M
- $15 million — to pay to the Company a one-time fee of $15 million in consideration for the rights granted
- $130 million — stone payments of up to an aggregate of $130 million for the first Licensed Product to achie
- $175 million — stone payments of up to an aggregate of $175 million per Licensed Product and (b) tiered, es
Filing Documents
- tm2423222d1_8k.htm (8-K) — 27KB
- 0001104659-24-097152.txt ( ) — 196KB
- vygr-20240903.xsd (EX-101.SCH) — 3KB
- vygr-20240903_lab.xml (EX-101.LAB) — 33KB
- vygr-20240903_pre.xml (EX-101.PRE) — 22KB
- tm2423222d1_8k_htm.xml (XML) — 3KB
01 Entry into a Material Definitive
Item 1.01 Entry into a Material Definitive Agreement Amendment to Option and License Agreement with Novartis Pharma AG On September 3, 2024 (the "Amendment Effective Date"), Voyager Therapeutics, Inc. (the "Company") and Novartis Pharma AG ("Novartis") entered into an amendment (the "Amendment") to the Option and License Agreement between the Company and Novartis dated March 4, 2022 (the "Agreement"). Pursuant to the Amendment, the Company and Novartis agreed to amend the Agreement to incorporate the grant from the Company to Novartis of an additional license (the "License") to a capsid discovered through the Company's TRACER discovery platform (the "Licensed Capsid") for exclusive use with a certain gene (the "Direct License Target") to develop and commercialize the Licensed Capsid as incorporated into products containing a payload directed to the Direct License Target ("Licensed Products"). As a result of the Amendment, the Direct License Target is now deemed a Licensed Target under the Agreement, as such term is defined therein, and the License is subject to all other terms and conditions applicable to licenses granted to Novartis under the Agreement. Novartis agreed to pay to the Company a one-time fee of $15 million in consideration for the rights granted under the Amendment. The Company is eligible to receive specified development, regulatory, and commercialization milestone payments of up to an aggregate of $130 million for the first Licensed Product to achieve the corresponding milestone. On a Licensed Product-by-Licensed Product basis, the Company is also eligible to receive (a) specified sales milestone payments of up to an aggregate of $175 million per Licensed Product and (b) tiered, escalating royalties in the mid- to high-single-digit percentages of annual net sales of each Licensed Product. In connection with the Amendment, the parties acknowledged that Novartis' prior rights to exercise options for any initial targets and additional targets as
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 5 , 2024 VOYAGER THERAPEUTICS, INC. By: /s/ Alfred Sandrock, M.D., Ph.D. Alfred Sandrock, M.D., Ph.D. Chief Executive Officer, President, and Director (Principal Executive Officer)